Inicio/ABBV

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze ABBV in workspace
ABBVNYSE/health care

AbbVie Inc.

$248.00Down-0,08 (-0,03%)
Research reviewed: 12 jul 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

AbbVie Inc. operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
248,37
Hoch
249,74
Tief
244,61
Marktkapitalisierung
438,16 Mrd.
KGV
122.17
52-Wochen-Hoch
--
Dividende
2.790%
Quartalsdividende
--

3-month price context

El gráfico muestra la tendencia reciente de 3 meses para entender la estructura de corto plazo antes de abrir el workspace completo.

Investment thesis

Base case
Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. The base case remains conditional on humira erosion staying manageable.
Bull case
Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.
Bear case
Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.
Thesis invalidation
Reassess the thesis if humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition.

Key catalysts

  • Skyrizi and Rinvoq growth

    Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry.

  • Neuroscience momentum

    Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology.

  • Pipeline milestones

    Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Principal risks

  • Humira erosion

    Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition.

  • Oncology portfolio pressure

    Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand.

  • Government pricing exposure

    U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

Latest earnings research

2026 Q1

For the quarter ended March 31, 2026, AbbVie reported broad revenue growth led by immunology and neuroscience, while Humira and Imbruvica declines remained portfolio headwinds; management raised its full-year adjusted EPS guidance.

Valuation interpretation

  • A stronger valuation case depends on Skyrizi, Rinvoq, and neuroscience growth continuing to more than offset mature-brand erosion.
  • Pipeline execution can support a durable growth premium, while drug-pricing exposure and concentration in key products warrant an uncertainty discount.

Peer research

AMGNGILDVRTX

Recent news

Trefis · vor 13 Stunden

How Does LLY Stock Reach $2,100?

24/7 Wall St. · vor 13 Stunden

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Motley Fool · vorgestern

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

GuruFocus.com · vor 3 Tagen

Amazon, Microsoft and Meta Among HSBC Earnings Picks

Simply Wall St. · vor 3 Tagen

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

24/7 Wall St. · vor 3 Tagen

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

Data and research sources

Research updated: 12 jul 2026, 00:00 UTC
3 verified sources
AbbVie Reports First-Quarter 2026 Financial ResultsAbbVie Inc. · earningsVerified

Fetched: 12/7/2026, 0:00:00 UTC

Published: 29/4/2026, 0:00:00

Open original source
AbbVie Investor RelationsAbbVie Inc. · companyVerified

Fetched: 12/7/2026, 0:00:00 UTC

Open original source
AbbVie Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 12/7/2026, 0:00:00 UTC

Open original source

Continue in the research workspace

Keep ABBV in context, run a multi-agent analysis, and monitor thesis changes.

Analyze ABBV free

Explora todo el sistema de análisis

Cada etapa cumple una función concreta y deja un resultado auditable.

Metodología de análisisLeer informes de mercadoExplorar acciones

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista Fundamental

Analista Fundamental se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista de Noticias

Analista de Noticias se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Gerente de Riesgo

Gerente de Riesgo se especializa en la etapa de Monitorizar dentro de Riesgo y monitoreo y ordena el contexto para los siguientes roles.